<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13212">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01812707</url>
  </required_header>
  <id_info>
    <org_study_id>DFI12361</org_study_id>
    <secondary_id>U1111-1134-4749</secondary_id>
    <nct_id>NCT01812707</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Alirocumab SAR236553 (REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Three Doses of SAR236553 (REGN727) Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥100 mg/dL (≥2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the effect of alirocumab SAR236553 (REGN727) on low-density lipoprotein
      cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in
      patients with LDL-C ≥100 mg/dL (≥2.59 mmol/L) on ongoing stable atorvastatin therapy.

      Secondary Objectives:

      To evaluate the effects of alirocumab SAR236553 (REGN727) on other lipid levels after 12
      weeks of treatment in comparison with placebo.

      To evaluate the safety and tolerability of alirocumab SAR236553 (REGN727).

      To evaluate the development of anti-alirocumab SAR236553 (REGN727) antibodies.

      To evaluate the pharmacokinetics of alirocumab SAR236553 (REGN727).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of study participation will depend on the status of the patient at screening:
      21 to 27 weeks including a screening period of 1 to 7 weeks, a double-blind treatment period
      of 12 weeks, followed by an 8 week follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent change in calculated low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in calculated low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent and absolute changes in other lipid parameters</measure>
    <time_frame>At Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 1 mL alirocumab SAR236553 (REGN727) Dose 1 every 2 weeks through subcutaneous administration in the abdomen.
alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
Atorvastatin will be administered once daily in the evening at a stable dose as background therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 1 mL alirocumab SAR236553 (REGN727) Dose 2 every 2 weeks through subcutaneous administration in the abdomen.
Atorvastatin will be administered once daily in the evening at a stable dose as background therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 1 mL alirocumab SAR236553 (REGN727) Dose 3 every 2 weeks through subcutaneous administration in the abdomen.
Atorvastatin will be administered once daily in the evening at a stable dose as background therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of 1 mL alirocumab SAR236553 (REGN727) matching placebo every 2 weeks through subcutaneous administration in the abdomen.
Atorvastatin will be administered once daily in the evening at a stable dose as background therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab SAR236553 (REGN727)</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 1</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 3</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 1</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 3</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

        Patients with primary hypercholesterolemia treated with atorvastatin at stable dose of
        5-20 mg for at least 6 weeks prior to screening and likely to have LDL-C ≥100 mg/dL (≥2.59
        mmol/L) at the screening visit.

        OR Patients with primary hypercholesterolemia who are receiving a lipid-lowering treatment
        other than atorvastatin, or who are not at stable dose of atorvastatin 5-20 mg for at
        least 6 weeks prior to screening and who are likely to have LDL-C ≥100 mg/dL (≥2.59
        mmol/L) after the run-in period on atorvastatin therapy.

        Exclusion criteria:

          1. LDL-C &lt;100 mg/dL (&lt;2.59 mmol/L) at Week -1 (V1): At the first visit for patients who
             are being treated with stable dose of atorvastatin 5-20 mg for at least 6 weeks prior
             to screening period.

             OR After the run-in period on atorvastatin (5-20 mg) for patients receiving a lipid
             lowering treatment other than atorvastatin, or not at stable dose of atorvastatin
             5-20 mg for at least 6 weeks prior to screening period.

          2. Patients with type 1 diabetes

          3. Patients with type 2 diabetes treated with insulin, or without, and considered poorly
             controlled at screening.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Koganei-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392004</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
